NASDAQ:INO

Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision
····

Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision

Inovio Pharmaceuticals shares fell 2.7% to $1.275 after H.C. Wainwright cut its price target to $2.50, citing share dilution and focus on an FDA decision for INO-3107, expected by Oct. 30, 2026. Inovio’s share count rose to 82.3 million following a recent offering. Precigen’s rival RRP drug posted $21.6 million in Q1 sales. Inovio reported a first-quarter net loss of $19.7 million.
June 1, 2026

Stock Market Today

  • Wise Faces Investigation Over Alleged Money Laundering Controls in Europe
    June 1, 2026, 1:50 PM EDT. UK-based money transfer company Wise is under investigation by Belgian prosecutors over alleged money laundering control failures in its European operations, not its UK business. The probe focuses on suspicions that Wise accounts facilitated around €500 million in suspicious transactions across 30 European countries. Wise, which recently shifted its primary stock listing to the US Nasdaq, stated it is cooperating fully but has not received any formal findings yet. Shares plunged 17.5%, wiping more than £1 billion off its market value. The investigation could affect customer trust and lead to regulatory penalties if oversight lapses are confirmed. Founded in 2011, Wise serves over 19 million customers globally with 4.7 million daily transactions.